D
David E. Lanar
Researcher at Walter Reed Army Institute of Research
Publications - 115
Citations - 7209
David E. Lanar is an academic researcher from Walter Reed Army Institute of Research. The author has contributed to research in topics: Plasmodium falciparum & Antigen. The author has an hindex of 45, co-authored 114 publications receiving 6749 citations. Previous affiliations of David E. Lanar include Walter Reed Army Medical Center & Silver Spring Networks.
Papers
More filters
Journal ArticleDOI
Breadth and Magnitude of Antibody Responses to Multiple Plasmodium falciparum Merozoite Antigens Are Associated with Protection from Clinical Malaria
Faith H. A. Osier,Faith H. A. Osier,Gregory Fegan,Gregory Fegan,Spencer D. Polley,Linda M. Murungi,Federica Verra,Federica Verra,Kevin K. A. Tetteh,Brett Lowe,Tabitha W. Mwangi,Peter C. Bull,Alan W. Thomas,David R. Cavanagh,Jana S. McBride,David E. Lanar,Margaret J. Mackinnon,Margaret J. Mackinnon,David J. Conway,David J. Conway,Kevin Marsh +20 more
TL;DR: It is suggested that under natural exposure, immunity to malaria may result from high titers antibodies to multiple antigenic targets and support the idea of testing combination blood-stage vaccines optimized to induce similar antibody profiles.
Journal ArticleDOI
A field trial to assess a blood-Stage malaria vaccine
Mahamadou A. Thera,Ogobara K. Doumbo,Drissa Coulibaly,Matthew B. Laurens,Amed Ouattara,Abdoulaye K. Kone,Ando B. Guindo,Karim Traore,Idrissa Traore,Bourema Kouriba,Dapa A. Diallo,Issa Diarra,Modibo Daou,Amagana Dolo,Youssouf Tolo,Mahamadou S. Sissoko,Amadou Niangaly,Mady Sissoko,Shannon Takala-Harrison,Kirsten E. Lyke,Yukun Wu,William C. Blackwelder,Olivier Godeaux,Johan Vekemans,Marie-Claude Dubois,W. Ripley Ballou,Joe Cohen,Darby J. S. Thompson,Tina J. T. Dube,Lorraine Soisson,Carter L. Diggs,Brent House,David E. Lanar,Sheetij Dutta,D. Gray Heppner,Christopher V. Plowe +35 more
TL;DR: The malaria vaccine did not provide significant protection against clinical malaria, but on the basis of secondary results, it may have strain-specific efficacy.
Journal ArticleDOI
Long-Term Efficacy and Immune Responses following Immunization with the RTS,S Malaria Vaccine
José A. Stoute,Kent E. Kester,Urszula Krzych,Bruce T. Wellde,Ted Hall,Katherine White,G Glenn,Christian F. Ockenhouse,N. Garcon,Robert Schwenk,David E. Lanar,P Sun,P Momin,Robert A. Wirtz,C Golenda,Moncef Mohamed Slaoui,Glenn Wortmann,Carolyn A. Holland,Megan Dowler,Joe Cohen,William Ripley Ballou +20 more
TL;DR: Further optimization in vaccine composition and/or immunization schedule will be required to induce longer-lasting protective immunity in malaria sporozoite vaccine candidate RTS,S.
Journal ArticleDOI
Circumsporozoite protein heterogeneity in the human malaria parasite Plasmodium vivax
Ronald Rosenberg,Robert A. Wirtz,David E. Lanar,Jetsumon Sattabongkot,Ted Hall,Andrew P. Waters,Chusak Prasittisuk +6 more
TL;DR: Phenotypic heterogeneity in the repetitive portion of a human malaria circumsporozoite (CS) protein, a major target of candidate vaccines, has been found and implies that a P. vivax vaccine based on the CS protein repeat of one isolate will not be universally protective.
Journal ArticleDOI
Phase I/IIa Safety, Immunogenicity, and Efficacy Trial of NYVAC-Pf7, a Pox-Vectored, Multiantigen, Multistage Vaccine Candidate for Plasmodium falciparum Malaria
Christian F. Ockenhouse,Pei Fang Sun,David E. Lanar,Bruce T. Wellde,B. Ted Hall,Kent E. Kester,José A. Stoute,Alan J. Magill,Urszula Krzych,Linda Farley,Robert A. Wirtz,Jerald C. Sadoff,David C. Kaslow,Sanjai Kumar,L. W. Preston Church,James M. Crutcher,Benjamin Wizel,Stephen L. Hoffman,Ajit Lalvani,Adrian V. S. Hill,John A. Tine,Kenneth P. Guito,Charles de Taisne,Robin F. Anders,Toshihiro Horii,Enzo Paoletti,W. Ripley Ballou +26 more
TL;DR: While antibody responses were generally poor, cellular immune responses were detected in >90% of the volunteers and there was a significant delay in time to parasite patency in the groups of volunteers who received either the low or high dose of vaccine compared with control volunteers.